Practice | Clinical images

Hydatidiform mole in a 39-year-old woman

Aziz Slaoui MD, Aicha Kharbach MD PhD, Aziz Baydada MD PhD

■ Cite as: CMAJ 2022 September 12;194:E1215. doi: 10.1503/cmaj.220185

A 39-year-old woman (gravida 4, para 3) presented at 14 weeks' gestation to the emergency department with acute pelvic pain and substantial vaginal bleeding. Her blood pressure was 80/40 mm Hg and heart rate 114 beats/min. She was afebrile. Clinical examination showed mild suprapubic tenderness with distention. Immediate point-of-care ultrasound showed that her uterus contained echogenic structures with a "snowstorm" appearance. There were no visible embryonic or fetal structures. On speculum examination, the patient's vagina was full of blood clots with grapelike vesicles (Figure 1). We resuscitated the patient with intravenous fluids and transfused her with 4 units of packed red blood cells. We performed an urgent operative cervical dilatation and ultrasound-guided aspiration of the uterine contents. She received 20 IU intravenous oxytocin and the vaginal bleeding stopped. Pathologic examination confirmed the clinical diagnosis of molar pregnancy, showing a noninvasive complete hydatidiform mole. Chromosomal study showed a diploid 46 XX karyotype. A metastatic assessment of the patient (a chest radiograph and an abdominopelvic ultrasound) was negative. At follow-up 8 weeks later, her serum β human chorionic gonadotropin (hCG) levels were undetectable.

Hydatidiform mole is a gestational disorder in which the trophoblast proliferates uncontrollably, forming hydropic vesicles.¹ A complete hydatidiform mole is diploid and the result of an anucleate egg cell with only paternal DNA owing to duplication of a single sperm or, infrequently, 2 sperm. A partial mole is triploid and results from fertilization between a normal egg and duplicated sperm or 2 sperm. Neither pregnancy is viable.²³ The frequency of molar pregnancy varies from fewer than 1 in 1000 pregnancies in high-income countries, to more than 1 in 400 in lower-income countries.³⁴

Molar pregnancies present 2 serious threats for maternal morbidity and mortality: hemorrhage and neoplastic disease. The risk of hemorrhage is decreased with early diagnosis, before 12 weeks. Gestational trophoblastic neoplasia is diagnosed through serial hCG monitoring and imaging. Evidence of persistent elevation of serum hCG or metastases outside the uterus to pelvis, lung or beyond requires further treatment with chemotherapy.³

References

- Lurain JR. Gestational throphoblastic disease: epidemiology, pathology, clinical presentation and diagnosis of gestational throphoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol 2010;203:531-9.
- Sebire N, Fisher R, Foskett M, et al. Risk of recurrent hydatiform mole and subsequent pregnancy outcome following complete or partial hydatiform molar pregnancy. BJOG 2003:110:22-6.
- Eiriksson L, Dean E, Sebastianelli A, et al. Guideline No. 408: management of gestational trophoblastic diseases. J Obstet Gynaecol Can 2021;43:91-105.e1.
- Ngan HYS, Seckl MJ, Berkowitz RS, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 2018;143:79-85.




Figure 1: Photograph of a patient in the lithotomy position with heavy bleeding of vulvar origin, showing patient's legs (white arrow); characteristic appearance of a hydatiform mole (red arrow), with vesicles of variable size (from a few millimetres to 1.5–2 cm in diameter) with transparent walls; blood clots and fragments of the endometrial decidua; and surgical drapes (blue arrow).

Competing interests: None declared.

This article has been peer reviewed.

The authors have obtained patient consent.

Affiliations: Gynaecology-Obstetrics and Endoscopy Department (Slaoui, Baydada), Maternity Souissi, University Hospital Center IBN SINA; Gynaecology-Obstetrics and Endocrinology Department (Slaoui, Kharbach), Maternity Souissi, University Hospital Center IBN SINA, Mohammed V, Rabat University, Morocco.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

Correspondence to: Aziz Slaoui, azizslaoui27@gmail.com